

- Microbial pathogenesis (*Cont.*):
 tissue damage and disease, 145e-9–10
 tissue invasion, 145e-7–8
 tissue tropism, 145e-8–9
 transmission to new hosts, 145e-10
 Microbial source tracking, 86e-1t
 Microbiome. *See also* Human microbiome
 analysis of, 145e-1, 145e-4
 definition of, 86e-1, 425
 in infectious disease evaluation, 761
 Microbiomics, 6
 Microbiota, 86e-1, 86e-1t. *See also* Gut microbiota
 Microcytosis, 393, 398
 Microfilaria, 245e-1, 245e-6t
 β_2 -Microglobulin
 in amyloidosis, 719, 720t, 724
 laboratory evaluation of, 406, 2758t
 in multiple myeloma, 715–716, 716t
 Microimmunofluorescence test, 1171
 Micronucleus assay, 263e-7
 Micronutrient malnutrition, **461**. *See also specific micronutrients*
 MicroRNAs (miRNAs)
 in aging, 94e-3
 in AML, 681
 in cancer, 101e-7
 gene expression silencing by, 102e-8
 in stem cells, 455
 in viruses, 214e-6
 Microsatellite instability, 101e-1f, 101e-5
 Microscopic polyangiitis, **2186**
 clinical features of, 1835t, 1840, 2186
 definition of, 2186
 diagnosis of, 1840, 2186
 incidence and prevalence of, 2186
 lung biopsy in, 386e-5f, 1840
 pathogenesis of, 2186
 treatment of, 2186
 Microsomal ethanol oxidizing system (MEOS), 2058
 Microsporidia/microsporidiosis, **1408**
 clinical features of, 1408
 diagnosis of, 245e-1, 245e-4t, 245e-5t, 245e-6t, 1408
 epidemiology of, 245e-4t
 in HIV infection, 1257, 1408
 life cycle of, 245e-4t, 1408, 1408f
 treatment of, 1408
 Microtubules, 103e-14
 Microvascular angina, 1579
 Mid-arm muscle circumference, 462
 MIDAS (Migraine Disability Assessment Score), 2590, 2591f
 Midazolam
 for conscious sedation, 35
 for delirium, 64t, 65
 dosage in liver disease, 37
 drug interactions of, 246e-3t
 for dyspnea, 62t
 for nerve agent exposure, 262e-7
 overdose/poisoning with, 473e-10t
 for scorpion stings, 2748
 for status epilepticus, 2558f
 during terminal weaning, 67
 Midbrain stroke syndrome, 2580f
 Middle cerebral artery
 lesion in territory of, 178
 occlusion of, 440e-3f, 2572–2573, 2573f, 2581
 stenosis of, 441e-16f
 territory of, 2572f, 2573f
 Middle East respiratory syndrome (MERS), 261e-9, 1204–1205
 Middleton maneuver, 411
 Midline destructive disease, 2184
 Midline granuloma, 237
 Midodrine
 adverse effects of, 2644
 for ascites, 288
 for dialysis-related hypotension, 1824
 for hepatorenal syndrome, 1810
 for orthostatic hypotension, 146, 2644
 for postural orthostatic tachycardia syndrome, 1477
 Midpontine stroke syndrome, 2578f
 Mifepristone
 adverse effects of, 2273
 for Cushing's syndrome, 2273
 for postcoital contraception, 2391
 MIG (monokine induced by IFN- γ), 372e-12t
 Miglitol, 2414t
 Migraine, **2586**
 acephalgic, 2560, 2589
 autonomic symptoms in, 107
 channelopathies in, 444e-2t
 chronic, 2589
 classification of, 2587t
 clinical features of, 2588t, 2589
 cyclic vomiting in, 259
 diagnosis of, 2589, 2590t
 familial hemiplegic, 2589
 fatigue in, 152
 genetic considerations in, 444e-2t, 2589
 imaging in, 441e-43f, 2589, 2589f, 2590f
 ocular manifestations of, 204
 pathogenesis of, 89, 2586, 2588–2589, 2588f
 in pregnancy, 49
 prevalence of, 107t, 2586
 prevention of, 2593, 2593t, 2594t
 Raynaud's phenomenon and, 1649
 retinal, 201
 vs. stroke, 2560
 taste disorders in, 215
 treatment of, **2590**
 acute attack therapies, 2590, 2592t, 2593t
 5-HT₁ agonists, 2590–2591, 2592t
 disability assessment in, 2590, 2591f
 dopamine antagonists, 2591–2592, 2592t
 drug combinations for, 2592–2593
 nonpharmacologic, 2590
 NSAIDs, 2590, 2592t
 opioids, 2592t, 2593
 triggers, 2586
 vertigo in, 148
 vestibular, 150
 Migraine aura, 2589
 Migraine Disability Assessment Score (MIDAS), 2590, 2591f
 Migrainous neuralgia, 237
 Migrating motor complex, 264–265
 Mikulicz's disease, 391e-1. *See also* IgG4-related disease (IgG4-RD)
 Mild cognitive impairment (MCI), 75, 76f, 171, 175f, 2598
 Miliaria rubra, 479e-1
 Miliary tuberculosis, 138, 1108f, 1112, 1119
 Military recruits, adenovirus infections in, 1208
 Milk-alkali syndrome, 313, 2458, 2479
 Milk of calcium bile, 2082
 Milk of magnesia, 62t
 Millard-Gubler syndrome, 209
 Miller Fisher syndrome, 989, 2695, 2696t, 2698t.
See also Guillain-Barré syndrome (GBS)
 Miller's lung, 1681t
 Millipede dermatitis, 2750
 Milnacipran, 2240, 2240t
 Milrinone, 1509–1510, 1510t, 1763
 Milroy's disease (congenital lymphedema), 1653
 Miltefosine
 action of, 246e-10–11
 adverse effects of, 246e-5t, 1391
 for cutaneous leishmaniasis, 1393
 for free-living ameba infections, 1367, 1368
 pharmacology of, 246e-10–11
 for visceral leishmaniasis, 1391
 Milwaukee shoulder, 2236
 Mind-body interventions, 14e-3
 Mineral(s), **96e-9**. *See also specific minerals*
 absorption of, 1933
 assessment of nutritional status, 462
 body stores of, 96e-1
 deficiencies of, 96e-9t
 parental supplementation of, 98e-6t
 recommended intake of, 95e-3t
 reference ranges for, 2766t
 in specialized nutritional support formulas, 98e-5
 tolerable upper intake levels of, 96e-9t
 toxicities of, 96e-9t
 Mineralocorticoid(s)
 for adrenal insufficiency, 2326
 resistance to, 297
 synthesis of, 2309f, 2311, 2311f
 Mineralocorticoid excess, **2318**. *See also* Syndrome of apparent mineralocorticoid excess (SAME)
 clinical features of, 2319
 diagnosis of, 2319, 2320f
 differential diagnosis of, 2319, 2320f
 epidemiology of, 2318
 etiology of, 2318–2319, 2318t, 2320t
 pathophysiology of, 64e-8, 64e-8f
 treatment of, 2319–2320, 2320f
 Mineralocorticoid receptors, 297, 306, 310
 Mineral oil, vitamin A absorption and, 96e-6
 Minimal bactericidal concentration (MBC), 150e-9
 Minimal change disease
 clinical features of, 1835t, 1841–1842
 pathogenesis of, 1841–1842, 1842f
 proteinuria in, 293, 1805, 1834, 1842
 renal biopsy in, 62e-1f, 1841–1842
 treatment of, 1842
 Minimal erythema dose, 389
 Minimal fungicidal concentration (MFC), 150e-9
 Minimal inhibitory concentration (MIC), 150e-9, 935
 Minimally conscious state, 1771
 Minimally invasive adenocarcinoma, 515–516
 Mini-Mental Status Examination (MMSE)
 in delirium evaluation, 64, 168
 in dementia evaluation, 173
 in neurologic examination, 2537
 Mini Nutritional Assessment, 81, 276
 Minitransplant, 103e-20, 636, 703
 Minocycline
 for acne rosacea, 352
 for acne vulgaris, 352
 for actinomycosis, 1091t
 action of, 930, 931t, 943
 adverse effects of, 943
 cutaneous, 379
 fever, 138
 hyperpigmentation, 360, 361
 hypersensitivity, 382. *See also* Drug-induced hypersensitivity syndrome (DIHS)
 oral lesions, 240t
 vasculitis, 363, 2218t
 indications for, 940t, 943
 for *Legionella* infections, 1020t
 for leprosy, 1126, 1127
 for MRSA infections, 345, 962t
 for *Nocardia* infections, 1087
 for osteomyelitis, 841t
 resistance to, 931t, 940t
 for sarcoidosis, 2211
 for staphylococcal skin/soft tissue infections, 962t
 for Whipple's disease, 1094
 Minor histocompatibility antigens, 373e-6
 Minor histocompatibility loci, 373e-6
 Minoxidil
 adverse effects of, 253t, 332, 380, 1625
 for androgenetic alopecia, 355t
 development of, 43
 for hypertension, 1624t
 Miosis, 473e-3, 1774
 MIP-1 α (macrophage inflammatory protein-1 α), 372e-12t, 1241
 MIP-1 β (macrophage inflammatory protein-1 β), 372e-12t
 Mipomersen, 2448t, 2449
 Mirizzi's syndrome, 2081
 miRNAs. *See* MicroRNAs (miRNAs)
 Mirror neuron systems, 444e-12
 Mirtazapine
 adverse effects of, 2392, 2710t, 2717
 for depression, 63–64, 2710t, 2717